| Gene symbol | TP53 | Synonyms | BCC7, BMFS5, LFS1, P53, TRP53 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | tumor protein p53 | ||||
| GTO ID | GTC0031 |
| Trial ID | NCT00393029 |
| Disease | Metastatic Melanoma | Metastatic Cancer |
| Altered gene | P53 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | P53 TCR-T cells |
| Co-treatment | Filgrastim |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes |
| Year | 2006 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 070003|070003|07-C-0003 |
| Vector information | |||
|
|||
| Cohort1: Metastatic Melanoma | |||||||||||||
|
|||||||||||||
| Cohort2: Other Metastatic Cancers | |||||||||||||
|
|||||||||||||